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A couple with a proband child of GJB2 (encoding the gap junction protein connexin 26)-associated hearing impairment and a 
previous pregnancy miscarriage sought for a reproductive solution to bear a healthy child. Our study aimed to develop a cus-
tomized preconception-to-neonate care trajectory to fulfill this clinical demand by integrating preimplantation genetic diagno-
sis (PGD), noninvasive prenatal testing (NIPT), and noninvasive prenatal diagnosis (NIPD) into the strategy. Auditory and ge-
netic diagnosis of the proband child was carried out to identify the disease causative mutations. The couple then received 
in-vitro-fertilization treatment, and eight embryos were obtained for day 5 biopsy. PGD was performed by short-tandem-repeat 
linkage analysis and Sanger sequencing of GJB2 gene. Transfer of a GJB2c.235delC heterozygous embryo resulted in a sin-
gleton pregnancy. At the 13th week of gestation, genomic DNA (gDNA) from the trio family and cell-free DNA (cfDNA) 
from maternal plasma were obtained for assessment of fetal chromosomal aneuploidy and GJB2 mutations. NIPT and NIPD 
showed the absence of chromosomal aneuploidy and GJB2-associated disease in the fetus, which was later confirmed by inva-
sive procedures and postnatal genetic/auditory diagnosis. This strategy successfully prevented the transmission of hearing im-
pairment in the newborn, thus providing a valuable experience in reproductive management of similar cases and potentially 
other monogenic disorders.  
preimplantation genetic diagnosis (PGD), noninvasive prenatal testing (NIPT), noninvasive prenatal diagnosis (NIPD), 
GJB2 (encoding the gap junction protein connexin 26), hearing impairment 
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Hereditary hearing loss is a highly heterogeneous disease 
affecting approximately one in 500 newborns [1]. Prenatal 
diagnosis of hereditary hearing loss relies on genetic testing 
samples obtained from amniocentesis or chorionic villus 
sampling. These procedures involve minor risk of fetal loss, 
and cause mental stress to patients and their family [2,3]. 
New technologies such as pre-implantation genetic diagno-
sis (PGD) and non-invasive prenatal diagnosis (NIPD) can 
prevent the recurrence of the disease and avoid repeated 
invasive diagnosis, thus offering alternative reproduction 
choices to women with the risk of pregnancy with heredi-
tary hearing loss. Since 2009, PGD for hearing impairment 
has been performed in Europe and Taiwan [46]. For in-
stance, Altarescu et al. reported PGD for nonsyndromic 
deafness by Sanger sequencing and short tandem repeat 
(STR) linkage analysis of polar body and blastomere [7]. 
Recently, Meng et al. also demonstrated that by massively 
parallel sequencing (MPS) of genomic DNA (gDNA) from 
a family with autosomal recessive congenital deafness and 
maternal plasma DNA, the fetal condition of the deafness 
causative mutation can be accurately predicated by NIPD 
using single nucleotide polymorphism (SNP)-based chro-
mosome phasing and haplotype-assisted analysis [8]. Well- 
designed integration of such technologies can improve the 
reproductive care for patients and their families. In contrast, 
providing different tests, lacking in strategic integration and 
less-considered workflow, may pose a great challenge for 
both patient and clinicians to understand the technical 
backgrounds and testing results. In case of discrepant results 
between different tests, misunderstanding of the disease 
may hinder the timely treatment of disease.  
In this study, we aimed to develop a preconception-to- 
neonate testing strategy for the couple who bore the child 
with the hearing loss. We provided auditory and genetic 
diagnosis for a family with GJB2 (encoding the gap junc-
tion protein connexin 26)-associated non-syndromic hearing 
loss. More importantly, we coordinated services at different 
medical centers to provide various preconception and pre-
natal tests, including PGD, noninvasive prenatal testing 
(NIPT), NIPD, and postnatal confirmation. 
1  Materials and Methods 
1.1  Study overview 
Auditory and genetic diagnosis was performed by the Oto-
laryngological Department of the PLA General Hospital. In 
vitro fertilization (IVF)-PGD and prenatal healthcare was 
collaborated by the PLA General Hospital and the Repro-
ductive Hospital Affiliated to Shandong University. NIPT 
and NIPD were performed at the Clinical Laboratory of 
BGI. Post-test auditory and genetic confirmation was per-
formed at the Chinese PLA General Hospital and Clinical 
Laboratory of BGI-Shenzhen. The entire process was coor-
dinated and overall genetic counseling was provided by 
clinicians from the Otolaryngological Department of the 
Chinese PLA General Hospital. Specific pre-test counseling 
and opt-out choice was provided to the family before each 
individual test, and informed consent was obtained before 
each test. Ethical approvals were obtained from the Chinese 
PLA General Hospital Institution Review Board of the Eth-
ics Committee, the Reproductive Hospital Affiliated to 
Shandong University Institutional Review Board, and the 
Institutional Review Board of BGI for this research. 
1.2  Auditory and genetic diagnosis of GJB2-assocatied 
hearing loss 
For auditory diagnosis of the proband child, physical exam-
ination, tympanometry, acoustic reflex, normal auditory 
brainstem response (ABR), distortion product otoacoustic 
emission (DPOAE), 40Hz auditory event related potential 
test (AERP) and auditory data analysis was carried out us-
ing the standard protocol described above [9]. For genetic 
diagnosis, gDNA was extracted from the father, the mother 
and the proband child. Primer pairs were synthesized to 
amplify the mitochondrial DNA (mtDNA) 12SrRNA, the 
second exon of GJB2, and exon 8, 10, 15, 18 of SLC26A4 
including the flanking sequences [10]. PCR products were 
directly sequenced by ABI 3730 Sequencer (Applied Bio-
systems). 
1.3  IVF-PGD treatment 
After completing the necessary physical examination and 
biochemical and hormone test, the couple received treat-
ment of GnRH (gonadotropin-releasing hormone) agonist 
and recombinant FSH (Gonal-F). Follicles were monitored 
by ultrasound. Fourteen mature oocytes were retrieved for 
intracytoplasmic sperm injection (ICSI) treatment and eight 
embryos were obtained. Blastocysts’ biopsies were con-
ducted on day 5 or 6. 
Preimplantation diagnosis of GJB2c.235delC/c.299- 
300delAT was based on multiplex nested PCR and short 
tandem repeat (STR)-based linkage analysis. Seven STR 
markers (GJB2-AT2, D13S1830, D13S633, D13S250, 
D13S1275, D13S232, and D13S292) and associated for-
ward/reverse primers were selected from a previously re-
ported study [7] for linkage analysis (Supplemental Materi-
al). Size discrimination of the STR makers was achieved by 
capillary electrophoresis analysis (3500 Genetic Analyzer 
Capillary Array, 36 cm). gDNA of the parents and proband 
was extracted from their peripheral blood (QIAgene) fol-
lowing the manufacturer’s instruction. Blastocysts’ analysis 
was carried out by a two-step multiplx PCR method (Sup-
plementary Method and Table S1 in Supporting Infor-
mation). PCR products were diluted and run on an ABI 
Prim 3500 Avant automated sequencer, and analyzed using 
GeneMapper software using the default setting and follow-
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ing the manufacturer’s instructions. To directly show the 
GJB2 genotype of the embryos, primers were also used to 
amplify the second exon of GJB2 (Table S2 in Supporting 
Information) for direct sequencing. 
1.4  NIPT for fetal aneuploidy  
At the 13th gestational week, 5 ml peripheral blood of   
the parents and 2 ml of the proband were collected into tubes 
containing EDTA. For NIPT, 2.5 ml of maternal blood   
was ice-centrifuged twice to extract plasma as described 
above [11], while the remaining samples were used for 
NIPD. Plasma was frozen and delivered to the BGI Clinical 
Laboratories where it was prepared for cell-free DNA 
(cfDNA) extraction, library construction, quality control, 
and pooling. Low-coverage whole-genome sequencing was 
performed with the BGISEQ-100 platform. This platform 
has been approved by the China Food and Drug Administra-
tion for NIPT. A barcode tracking system was employed 
during sample preparation. Eleven bases of sequencing reads 
were trimmed and aligned to a universal unique read set in-
cised from the human reference genome (hg18, NCBI build 
36). At least three million unique “after-alignment” se-
quencing reads were used for bioinformatics analysis. A 
binary hypothesis t-test and a logarithmic likelihood ratio 
L-score between the two t-tests were used to classify fetal 
autosomal aneuploidy of trisomy 21 (T21), trisomy 18 
(T18), and trisomy 13 (T13), as described earlier [12]. 
1.5  NIPD of GJB2-associated hearing loss  
gDNA of both parents and the proband was extracted from 
peripheral blood (TIANamp Blood DNA Kit, TIANGEN) 
and fragmented by sonication (Covaris), yielding fragments 
with an average size of 200250 bp. A sequencing library 
of gDNA was prepared by four cycles of PCR. This was 
performed with index primers following procedures of 
end-repair, “A”-overhanging and adapter-ligation. cfDNA 
extracted from maternal blood was used to prepare the li-
brary with the KAPA library preparation kit (KAPA Bio-
systems) according to the manufacturer’s protocol. After the 
ligation of the adapter, eight cycles of PCR were performed 
with index primers. 
Enrichment of the GJB2 target region was performed by 
a customized NimbleGen SeqCap EZ array (4 M region 
covering exons of GJB2 and highly heterozygous SNPs 
located 1 Mb upstream and downstream of GJB2) following 
the manufacturer’s instructions. Post-capture libraries were 
amplified by a 14-cycle PCR, and then sequenced using a 
HiSeq2500 platform (Illumina) with 90-bp paired-end se-
quencing. 
BWA software (0.7.12) was used to map the paired-end 
reads to the human reference genome (hg19, build 37) with 
the default parameters. Then the SNPs calling were per-
formed using the GATK software and the filter criteria of 
depth≥40 and quality value>20. SNPs, homozygous in 
both parents, but with different genotypes, were used for 
calculating fetal DNA fraction using the formula: fetal DNA 
fraction=2dfather/(dmother+dfather), where dmother and dfather stand 
for the allele count of the special base of the mother and the 
father respectively. A strategy of trios analysis based on 
Mendel′s law was used to deduce the parental haplotype, 
and a Hidden Markov Model and Viterbi algorithm were 
used to calculate the inherited status of maternal haplotype 
or paternal haplotype respectively [8,13,14]. 
Amniocentesis was performed at the 19th week of gesta-
tion and DNA from 20 ml amniotic fluid was extracted. 
PCR and Sanger sequencing were applied to analyze the 
GJB2 gene mutations, using the primers and reaction condi-
tions in Supplement Materials. 
1.6  Auditory examinations of newborns 
Twenty-four hours after delivery, the newborn child    
received neonatal hearing screening by AABR and  
DPOAE [15]. At two months after delivery, the child re-
ceived auditory diagnosis by ABR and 40Hz following the 
standard protocol described above [9]. 
2  Results  
2.1  Case presentation 
The parents of of a four-year-old child with delayed lingual 
development and hearing impairment was referred to our 
department in July 2010 (Figure 1). At the time of visit, the 
proband child was wearing a hearing aid and had severe 
recurrent otitis externa. The proband was born by natural 
pregnancy with no known family history of genetic disease 
except a cousin with Down syndrome (T21). Auditory di-
agnosis (ABR, DPOAE, 40Hz AERP, auditory steady-state 
response (ASSR), and visual reinforcement audiometry) of 
the proband indicated severe bilateral sensorineural hearing 
impairment. The proband then received temporal high reso-
lution computed tomography (HRCT) and brain magnetic 
resonance imaging, and was suggested to receive cochlear 
implantation, which was performed in July 2011. Mean-
while, the parents and proband were tested for GJB2, 
SLC26A4, and 12SrRNA to identify the disease-causative 
mutation. Sanger sequencing of these genes confirmed that 
the proband contained compound heterozygous mutations of 
c.235delC/c.299-300delAT of the GJB2 gene, while both 
parents were carriers of the disease (Figure 2). After genetic 
counseling, we organized a whole trajectory of reproductive 
management for this couple, including IVF-PGD, NIPT/ 
NIPD, and postnatal confirmation. 
2.2  IVF and PGD 
The couple received reproductive counseling and treatment  
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Figure 1  Timescale of the reproductive management of GJB2-associated hearing loss in a family desired to have a hearing normal child. GA, gestational age. 
of IVF and PGD in Oct 2013. One IVF cycle was performed 
by a standard IVF protocol, and 14 oocytes were retrieved 
through ICSI treatment. Eight embryos were obtained for 
day 5 biopsy. DNA was extracted from the trophectoderm 
cells of each embryo and analyzed for GJB2 and STR mak-
ers by Sanger sequencing and multiplex nested PCR. Both 
DNA sequencing and linkage analysis showed that five 
among eight embryos were carriers of the GJB2-associated 
hearing loss, while the remaining three embryos contained 
compound heterozygous mutations (Figure 2). After genetic 
counseling, the couple decided to accept embryo transfer of 
a carrier embryo. Thus single embryo transfer using the 
embryo #13 was performed in May 2013, resulting in a 
successful singleton pregnancy confirmed by hCG (human 
chorionic gonadotropin) 12 days after transfer and by ultra-
sound examination 35 days after transfer. 
2.3  Prenatal testing for fetal aneuploidy and GJB2 as-
sociated hearing loss 
The pregnancy was classified as high-risk owing to the fam-
ily history of hearing loss, IVF treatment, and a T21 family 
member in the pedigree. At the 13th week, 5 ml of maternal 
blood was collected with informed consent, and plasma 
DNA was tested for fetal aneuploidy and GJB2-associated 
hearing loss by NIPT and NIPD respectively. Low risk of 
T21 (t=0.98), T18 (t=0.54), and T13 (t=0.04) was re-
ceived by NIPT, and no other pathogenic chromosome dele-
tion or duplication was observed (Figure 3 and Figure 4). 
To test for GJB2-associated mutation by NIPD, approx-
imately 164 kb target region covering the exons of GJB2 
sequence and flanking SNPs was sequenced in the mother, 
the father, the proband and the maternal plasma, using a 
customized Nimble Gen SeqCap EZ array. SNPs obtained 
from the parents and proband were used to construct the 
parental haplotype, while the successfully phased SNPs in 
the maternal plasma cfDNA were used for fetal haplotype 
deduction. The fetal haplotype was deduced with a Hidden 
Markov Model via two steps: (i) predicting the paternal 
transmitting haplotype by SNPs heterozygous in father, 
while homozygous in mother; (ii) predicting the maternal 
transmitting haplotype by SNPs heterozygous in mother, 
while homozygous in father. 
Table 1 shows the statistics of target sequencing after 
removing duplication. A mean sequencing depth of 
130.91x, 116.38x, and 176.04x was respectively obtained in 
the GJB2 gene from the mother, father, and proband, re- 
sulting in 436, 443 and 423 SNPs for haplotype analysis. 
One hundred and sixty four SNPs were successfully phased, 
of which 73 SNPs were used to deduce paternal inherited 
haplotype and 91 SNPs were used to deduce maternal inher-
ited haplotype. A total of 3.94 Gb raw data was obtained 
from sequencing maternal plasma DNA. After filter of du- 
plication, a mean depth of 188.4x was obtained in the GJB2 
gene, covering 99.56% of the target region. The fraction of 
fetal cfDNA in the maternal plasma was estimated as 15%. 
Prediction of fetal haplotype showed that the fetus inherited 
the GJB2c.235delC allele from the mother, and the non-
pathogenic allele from the father; thus indicating a carrier 
status (Figure 5A). To confirm the results, amniocentesis 
was performed at the 20th week, and prenatal diagnosis of 
fetal GJB2 gene by Sanger sequencing was applied. These 
showed that the fetus was, as expected, a carrier of 
GJB2c.235delC (Figure 5B). 
2.4  Auditory and genetic examinations after birth 
In January of 2015 a male baby weighing 3,150 g was de- 
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Figure 2  Genetic diagnosis of the hereditary hearing loss in the family and PGD of the GJB2 mutation in eight embryos after IVF treatment. Sanger se-
quencing of GJB2 showed that the parents were carriers of c.299-300delAT and c.235delC respectively, whereas the proband and the first fetus inherited 
both alleles from the parents. STR analysis using seven STR markers showed that five embryos were carriers of the disease (#2, #7, #9, #11, #13), and three 
embryos (#1, #5, #8) were compound heterozygous of GJB2c.299-300delAT/c.235delC. Development of embryos was morphologically evaluated on day 5 
or day 6. The sizes of PCR products for STR markers are shown for the couple, the proband and embryos. The alleles in red and blue color indicated mutated 
alleles from father and mother, respectively. The green alleles indicate cross-over events.  
Table 1  Sequencing characteristics of NIPD of GJB2-associated hearing loss in the family 
 Data (Gb) 
Total SNP 
markers 
GJB2 region for targeted sequencing 
Reads mapped to 
target region Mean depth Depth20x (%)
No. of SNP 
markers Phased SNPs 
Mother 2.36 11251 0.33M 130.91x 99.11% 436 164 
Father 1.93 12320 0.29M 116.38x 98.66% 443 164 
Proband child 2.91 12019 0.44M 176.04x 99.24% 423 164 
Plasma 3.94 11670 0.77M 188.40x 99.56% 441 164 
 
livered at the 39th week of gestation with apparently normal 
phenotypes. The newborn baby passed the neonatal auditory 
screening by DPOAE and AABR at 24 hours after delivery. 
Therefore, PGD and NIPT/NIPD results were verified by 
neonatal phenotypes and genetic confirmation. Further di-
agnostic audiology tests at two months after birth confirmed 
that the newborn is with normal hearing (Figure S1 in Sup-
porting Information). 
3  Discussion  
We report the successful birth of a child free of GJB2-  
associated hereditary hearing loss through a preconception-  
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Figure 3  NIPT results at 13th gestation week for testing T21 (A), T18 
(B), T21 (C). The tested sample representing by the blue triangle had the 
T-score <0.25 and L-score <1 of all three chromosomes, suggesting the 
low risk of aneuploidy of these three chromosomes. Green circles stands 
for control sets with known euploid karyotypes. 
to-newborn care solution integrating IVF-PGD and 
next-generation sequencing (NGS)-based NIPT/NIPD. In 
this clinical case, the family was facing a difficult situation 
involving a proband child with GJB2-related hearing loss, a 
sibling with Down syndrome, and a singleton pregnancy 
conceived by IVF treatment. For the patient’s best benefits, 
a coordinated solution covering disease diagnosis, pre-  
implantation testing, prenatal testing, and neonatal confir-
mation was customized for this family. These efforts effec-
tively reduced the patient’s difficulty in selecting proper 
clinical care. Owing to this integrated management, precise 
genetic counseling was quickly provided to the patient, col-
lectively contributing to a good clinical outcome.  
In this study, PGD was performed using both STR-based 
linkage analysis and direct sequencing of the GJB2 muta-
tion. This approach reduced such technical risks as allelic 
drop out, amplification failure, and recombination event [7]. 
Thus the accuracy of this PGD method can be guaranteed. 
A day 5 blastocyst, rather than a day 3 blastocyst, was used 
for biopsy in order to have developmentally more compe-
tent embryos for diagnosis. Such an approach has been 
suggested to have technical advantages and an improved 
pregnancy rate [16,17]. Nonetheless, misdiagnosis can oc-
cur during PGD, and several types of errors causing adverse 
pregnancy outcomes have been reported [18]. Recently the 
haplotype-assisted NIPD was successfully applied in the 
prenatal diagnosis of maple syrup urine disease [13]. Sever-
al other monogenic diseases have also been validated with 
this haplotype-assisted method. This approach sequenced 
the entire exons of the target gene and the flanking hetero-
zygous SNPs, thus providing over 99% accuracy when con-
structing fetal haplotype [8,1922]. In this study, the the 
father and mother had a low tolerance for invasive testing 
due to a tragic experience in a previous pregnancy. Thus the 
haplotype-assisted NIPD was adopted and it was offered as 
an option in addition to the standard procedures. After 
counseling with regard to the benefit and limitation of the 
technology, the couple decided to receive NIPD for earlier 
anxiety relief. The NIPD result was in concordance with the 
PGD result and invasive confirmation which confirmed the 
high accuracy and reliability of the technology. At the end 
of the management, clinical outcomes were evaluated by 
newborn hearing screening and final auditory diagnosis. 
The results of these provided the definitive evidence needed 
to safely discharge the case from the hospital.  
At the time of sample collection for NIPD at the 13th 
gestational week, a maternal blood sample was also used to 
evaluate fetal chromosome aneuploidy by NIPT. This is 
important because IVF pregnancy has a high probability of 
chromosomal abnormality in embryos [6,2324]. Moreover, 
the family reported that a relative having Down syndrome 
was in the pedigree. Thus the current pregnancy was classi-
fied as high-risk. Owing to the integration of NIPT and 
NIPD at an early prenatal stage, chromosomal aneuploidy 
and GJB2 mutation were both evaluated in the fetus with 
one-step of sample collection. This provided the most com-
prehensive results for relief of the patient’s anxiety. 
The successful PGD in this study required extensive ef-
fort in optimizing appropriate STR loci and PCR conditions. 
This process was time-consuming and laborious, leading to 
prolonged turnaround time and elevated mental stress for 
the patient. Furthermore, the current PGD protocol cannot 
be used to identify chromosome aneuploidy of candidate 
embryos after IVF treatments. Recent application of sin-
gle-cell whole-genome amplification and NGS in preim-
plantation testing showed the detection of chromosomal 
aneuploidy, copy number variant, and even single-base mu-
tation in embryos [2528]. Thus it is possible to simultane-
ously test for chromosome aneuploidy and single gene dis-
ease using NGS-based PGD and preimplantation genetic  
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Figure 4  NIPT results at 13th gestation week for testing chromosome copy number variants. No. >10 Mb duplication marked by green events or deletion 
marked by red events were not detected. 
screening (PGS). For future development, NGS-based pre-
conception-to-neonate tests may add extra benefits to the 
clinical utility by reducing technical barriers between dif-
ferent tests. 
The cost of this management strategy is expensive, which 
can be a major obstacle for clinical application. However, 
economically this may still be a better choice compared to 
the expense of cochlear implantation and lifelong rehabilita-
tion, which is the only treatment for congenital profound 
hearing impairment. Moreover, as the sequencing cost rap-
idly reduces, future application of this trajectory could be 
more cost-effective, especially if NGS-based tests are used 
to cover different tests from preconception to postnatal 
stage.  
As a validation study of the pre-conception-to-neonate 
care strategy, the accuracy of the genetic methods (i.e. 
PGD, NIPT, and NIPD) was verified by several confirma-
tory tests. With accumulated evidence and proven efficacy, 
some of these confirmatory tests can be omitted in the  
future application to reduce the patient’s burden. Currently, 
such invasive procedures as chorionic villus sampling 
(CVS) and amniocentesis remain the golden standard     
of prenatal diagnosis, and NIPD cannot substitute for  
conventional invasive procedures. However, the result    
in this study, as well as several previous validation stu-   
dies, [8,1314,1922] showed that NIPD has the feasibility 
of providing accurate and reliable diagnosis just as invasive 
tests. This can be particularly important to patients receiv-
ing IVF-PGD treatment or with conditions inappropriate for 
invasive procedures. Further studies are still required to 
evaluate the potential of replacing invasive testing in this 
subgroup of pregnancy by NIPD. 
Supported by the NGS technology, the benefit of the 
testing strategy presented in this study is obvious. Never-
theless, the strategy also raised challenges of integrating 
new technologies into clinical practice, especially when the 
clinical utility is not fully evaluated. Further study is still 
required to validate the strategy and standardize the clinical 
workflow. In conclusion, the presented case demonstrates 
an integrated strategy of reproductive management of 





































































































































GJB2 c.235 in amniotic fluid DNA






Figure 5  NIPD and invasive confirmation results of GJB2-associated hearing loss in the fetus. A, the deduced fetal haplotype of chromosome 13 where 
GJB2 locates. X-Axis represents the loci on chromosome 13, and Y-axis represents the logarithmic values of the odd ratios in different combinations of the 
fetal haplotype. The paternal-originated haplotype and maternal-originated haplotype was shown by the grey and red lines respectively. The maternal haplo-
type 0 was the pathogenic haplotype which carries the c.235delC mutation, while maternal haplotype 1 was nonpathogenic; paternal haplotype 0 was the 
pathogenic haplotype which carries the c.229-300delAT mutation, and paternal haplotype 1 was nonpathogenic. NIPD result showed that the fetus carries the 
maternal haplotype 0 and paternal haplotype 1, thus the fetus carries the heterozygousc.235delC mutation. B, Sanger sequencing using amniotic fluid DNA 
confirmed the NIPD results, showing the heterozygous c.235delC mutation and wild type of c.229-300delAT. 
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GJB2-associated hearing loss. This approach can effectively 
stop the transmission of the hearing-related disease to the 
next generation, and has a potential to be used for other ge-
netic disorders. 
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